Alfasigma to Acquire Intercept Pharma for ~$794M
Shots:
- Alfasigma to acquire all issued and outstanding shares of Intercept common stock for $19.00 per share in cash representing a premium of 82% to Intercept’s closing stock price on Sept 25, 2023. The transaction is expected to close at the end of 2023
- The acquisition will expand Alfasigma’s portfolio in gastroenterology & hepatology and bolster its presence in the US. The acquisition also adds Intercept's Ocaliva, a treatment for liver disease primary biliary cholangitis to Alfasigma's portfolio
- Ocaliva (farnesoid X receptor agonist) was approved in the US & multiple other jurisdictions for PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotx. in adults unable to tolerate UDCA
Ref: Intercept | Image: Intercept
Related News:- Acumen Pharmaceuticals Presents P-I Trial (INTERCEPT-AD) Results of ACU193 for Early Alzheimer’s Disease at AAIC 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
